EP3415517A1 — Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2018-12-19 · 7y expired
What this patent protects
The present invention relates to a crystalline form of 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea that exhibits an X-ray powder diffraction pattern having 2-theta (2θ…
USPTO Abstract
The present invention relates to a crystalline form of 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea that exhibits an X-ray powder diffraction pattern having 2-theta (2θ) peaks at approximately 8.932°, 16.607°, and 17.328° or peaks expressed in d values (Å) at approximately 9.893, 5.334, and 5.114.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.